Vitiligo is an autoimmune condition in which cells known as melanocytes are killed off in certain areas of the skin. Melanocytes produce melanin, a substance which gives the skin its pigmentation.

Incyte is preparing to take an oral JAK inhibitor into phase 3 trials for the skin depigmentation disease vitiligo, after reporting mid-stage data showing efficacy in patients with facial and full ...